To describe the effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid (SUA) in patients with type 2 diabetes mellitus (T2DM). PubMed, EMBASE, and CENTRAL were searched for randomized controlled trials of SGLT2 inhibitors in patients with T2DM up to Aug 10, 2017, without language or date restrictions. Thirty-one studies totaling 13,650 patients were included. SGLT2 inhibitors significantly decreased SUA levels compared with placebo, canagliflozin WMD -37.02 lmol/L, 95% CI [-38.41, -35 
Introduction
Chronic hyperuricemia is a well-known established risk factor for the development of gout, kidney stones, and nephropathy (Bobulescu and Moe, 2012; Grassi et al., 2013) . Recent epidemiological study found that elevated serum uric acid (SUA) levels has been associated with hypertension, atherosclerosis, cardiovascular disease, and chronic kidney disease (Feig et al., 2002) . The role of serum uric acid as an independent risk factor for cardiovascular disease was investigated using a systematic review and meta-analysis, and showed that hyperuricemia does increase the risk of cardiovascular disease and mortality (Kim et al., 2010) . Many different studies showed that hyperuricemia was as well an independent risk factor for hypertension (Kuwabara et al., 2014) . Sodium-glucose co-transporter 2 (SGLT2) inhibitor, a welltolerated (Loeffler et al., 2012) newly approved oral hypoglycemic drug, induce urine glucose excretion by inhibiting SGLT2 at the S1 segment of the proximal tubule (Desai et al., 2017) . SGLT2 inhibitors control blood glucose level and improve glycemic control in patients with T2D in an insulin independent method (Idris and Donnelly, 2009 ). Moreover, SGLT2 inhibitors are characterized by their added benefits to address unmet clinical needs, such as weight loss, blood pressure control, and possible lipid lowering effect (Kalra, 2014; Majewski and Bakris, 2015; Bolinder et al., 2014) . A post hoc analysis assessed the effect of canagliflozin on serum uric acid level in type 2 diabetes mellitus patients (Abdulghani et al., 2016) . Here, we aim to examine and to describe the effect of SGLT2 inhibitors on SUA level in patients with T2DM. Abbreviations: SGLT2, sodium-glucose co-transporter 2; RCTs, randomized controlled trials; CKD, chronic kidney disease; N, number of patients; CANA, canagliflozin; DAPA, dapagliflozin; EMPA, empagliflozin; PLA, placebo.
Materials and methods

Search strategy
identify eligible RCTs using relevant search terms described in (Table 1) . We identified articles published up to Aug 10, 2017, without restrictions on language, year of publication or publication status. An additional manual search of the references of included trials, relevant meta-analyses.
Study selection
Studies meeting the following criteria were included: (1) population: patients with T2DM; (2) intervention: SGLT2 inhibitor monotherapy or as add-on to other hypoglycemic therapy; (3) comparison: placebo control or standard care; (4) outcome: serum uric acid changes from baseline; and (5) design: randomized controlled trials (RCTs); (6) follow-up duration at least 12 weeks. Conference abstracts were excluded because of the lack of detailed information assessing the trials' characteristics, definition of outcomes and trial quality.
Data extraction and quality assessment
The following information was extracted: first author, year of publication, study design, sample size, patient characteristics, The Cochrane risk of bias tool was used to assess the quality of the RCTs based on five domains: random sequence generation (selection bias), allocation concealment (selection bias), blinding (performance bias and detection bias), incomplete outcome data (attrition bias) and selective reporting (reporting bias) ( Table 2 ).
Statistical analysis
Weighted mean differences (WMD) (95% CI) in SUA level were calculated using a random-effects model to evaluate each SGLT2 inhibitor separately and by dose. Heterogeneity was quantified using I 2 , with I 2 values > 50% representing moderate heterogeneity.
The significance level for all outcome and heterogeneity analyses was set at p 0.05. All outcomes were pooled using RevMan5.3 software.
Results
Characteristics of included trials
Of 2858 articles screened, 31 trials met the eligibility criteria (Fig. 1) . The following information were extracted from each eligible RCT: first author and publication year, patient characteristics (background treatments, mean age, race, baseline HbA1c, and BMI), interventions (control), mean BUN, creatinine, and eGFR levels, variance measure and the number of participants in the treatment and control arms for all reported periods (Table 2) . Baseline SUA levels were within normal reference ranges for all studies. (Fig. 2) . Canagliflozin 300 mg had the same effects as canagliflozin 100 mg compared with PLA for SUA levels, which were significantly increased compared with those receiving PLA WMD À36.25 lmol/L, 95% CI [À38.17, À34.34]; (Fig. 2) .
Outcome analysis
Dapagliflozin had the same effects as canagliflozin compared with PLA, which were significantly decreased compared with those receiving PLA, dapagliflozin 5 mg WMD À37.81 lmol/L, 95% CI [À42.29, À33.33], dapagliflozin 10 mg WMD À38.93 lmol/L, 95% CI [À50.03, À27.83]; (Fig. 3) .
For patients receiving empagliflozin 10 mg, SUA levels were significantly decreased compared with PLA WMD À37.51 lmol/L, 95% (Fig. 5) . No significant association was revealed between the UA lowering effect of specific SGLT2 inhibitor with either dose.
Discussion
In this systematic review, we mainly evaluated the effects of SGLT2 inhibitors on SUA levels in patients with T2DM, a decrease in SUA levels was observed for SGLT2 inhibitors compared with PLA.
The mechanism by which SGLT2 inhibitors reduce serum uric acid has not been clearly understood. However, some studies Fig. 2 . Meta-analysis of weighted mean difference and 95% confidence intervals for changes in serum uric acid level for canagliflozin. Fig. 3 . Meta-analysis of weighted mean difference and 95% confidence intervals for changes in serum uric acid level for dapagliflozin.
suggested that it may possibly involve the renal SLC2A9 (GLUT9) transporter. The SLC2A9 gene encodes a facilitative glucose transporter and has two splice variants that are highly expressed in the apical membrane of the proximal tubule in nephron, a key site for urate handling in the kidney, found to transport both uric acid and d-glucose. A study was done to clarify the mechanism that may lead to the decreased of uric acid, where serum uric acid and urinary excretion rate of uric acid were analyzed after the oral administration of luseogliflozin to healthy subjects. This study confirmed that serum uric acid decreased as a result of the increase in the urinary excretion rate of uric acid, which correlated with the increase in urinary glucose excretion. SGLT2 inhibitor treatment leads to an increase in glucose excretion in the urine, which could eventually lead to an increased exchange of uric acid in the apical membrane of tubular cells leading to an increased release of uric acid from blood into the urine, thus decreasing serum uric acid levels (Heerspink et al., 2013; Mcgill, 2014; Wilding et al., 2009 ). There was previous meta-analysis have been published (Zhao et al., 2017) . Compared with that previous study, we also considered SUA-reduction as a major outcome, and analyzed the effect of existing SGLT2 inhibitors on uric acid compared with placebo. It provides more accurate evidence for the reaction of reducing uric acid by SGLT2 inhibitors.
Some limitations of our meta-analysis, which may reduce the strength of the evidence, such as, the length of the experiment is inconsistent, background treatment was inconsistent, basal uric acid levels are inconsistent etc. Secondly, we did not exclude trials enrolling CKD patients, whose SUA level might be elevated throughout disease progression. We could not observed about direct interaction between SGLT2 inhibitor and major uric acid transporters in vitro study. Articles included were hardly clinical homogeneity, so the presence of heterogeneity is inevitably substantial.
Conclusion
In conclusion, SGLT2 inhibitors were found in general to reduce serum uric acid levels in patients with T2DM. Given the associated clinical disorders with hyperuricemia, it is of course beneficial to lower serum uric acid in T2DM, and therefore, given the beneficial effects that SGLT2 inhibitors were found to have on serum uric acid reduction, this would give them an advantage over other oral antidiabetic agents.
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